Company intelligence / Profile preview
Rivopharm
- Ownership
- Private
- Employees
- ~150
- Development stage
- Other
Overview
Rivopharm develops, manufactures and globally supplies generic small‑molecule pharmaceutical products across multiple therapeutic areas, including launches such as generic nicorandil, lacidipine, racecadotril and mexiletine, and has US FDA‑inspected cGMP manufacturing and ANDA approvals enabling commercial sales in the US and more than 50 other countries.[1][3][4][7]
- Therapeutic areas
- ImmunologyEndocrinologyCardiovascularNeurologyInfectious DiseasesGastroenterologyPsychiatry
- Modalities
- Small molecule
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Rivopharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rivopharm.